Immune Enhancement for Immunological Non-responders to ART (IMMUNE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01806870
Recruitment Status : Active, not recruiting
First Posted : March 7, 2013
Last Update Posted : February 1, 2018
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
David M. Guidot, MD, Emory University

Brief Summary:
The purpose of this study is to see if taking two nutritional supplements, zinc and SAMe (S-adenosylmethionine), can improve lung health and immune function in persons with HIV. You are being asked to volunteer because you have HIV (Human Immunodeficiency Virus) and you take anti-retroviral therapy (ART) medications.

Condition or disease Intervention/treatment Phase
HIV Dietary Supplement: Zinc and SAMe Not Applicable

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Immune Enhancement for Immunological Non-responders to ART
Study Start Date : March 2013
Actual Primary Completion Date : June 2017
Estimated Study Completion Date : June 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Nutritional Supplements Zinc and SAMe
Each subject will receive 1600mg of SAMe per day Men subjects will receive 30mg Zinc Women subjects will receive 25mg Zinc
Dietary Supplement: Zinc and SAMe
If a subject has side effects their dose of Zinc will be reduced. SAMe will remain the same dose.

Primary Outcome Measures :
  1. Immune Enhancement for Immunological Non-responders to ART [ Time Frame: First 6 months ]
    Optimize the dosing of dietary zinc and SAMe that restores redox balance and zinc bioavailability in the airways of a cohort of HIV-infected individuals who are 'immunological non-responders'

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 1. Subjects living with HIV-1 infection who have been on anti-retroviral therapy (ART) for a minimum of 18 months and:

    • are followed longitudinally for their HIV healthcare in one of the study sites in Atlanta or Seattle
    • meet criteria for immunological non-responsiveness as defined by adherence to ART and cluster of differentiation 4 (CD4) count <350 despite adequate retroviral suppression.
  • 2. Ability to give informed consent.

Exclusion Criteria:

  1. Documented history of cirrhosis or a total bilirubin ≥ 2.0 mg/dL.
  2. Documentation of left ventricular ejection fraction < 40% or myocardial infarction within the past 6 months.
  3. End-stage renal disease requiring dialysis or a serum creatinine ≥ 2 mg/dL.
  4. Spirometry with Forced vital capacity (FVC) or Forced expiratory volume in 1 second (FEV1) < 70% of predicted value.
  5. Diabetes
  6. Known or possible pregnancy or attempting to become pregnant.
  7. BMI < 17
  8. Age < 21
  9. Parkinson's disease: these are all b/c the SAMe risks sections states that these pts will not qualify
  10. Bipolar disorder
  11. Bleeding disorders such as thrombocytopenia or significant gastrointestinal bleeding within the past year

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01806870

United States, Georgia
Grady Hospital- Ponce De Leon Clinic
Atlanta, Georgia, United States, 30308
Atlanta VA Medical Center
Decatur, Georgia, United States, 30033
Sponsors and Collaborators
Emory University
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: David Guidot, MD Emory University

Responsible Party: David M. Guidot, MD, Principal Investigator, Emory University Identifier: NCT01806870     History of Changes
Other Study ID Numbers: IRB00062730
1R34HL117351-01 ( U.S. NIH Grant/Contract )
First Posted: March 7, 2013    Key Record Dates
Last Update Posted: February 1, 2018
Last Verified: January 2018

Keywords provided by David M. Guidot, MD, Emory University:

Additional relevant MeSH terms:
Trace Elements
Growth Substances
Physiological Effects of Drugs